Valneva commences rolling submission to mhra for its inactivated, adjuvanted covid-19 vaccine

Saint-herblain (france), august 23, 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling submission, for initial approval of its covid-19 vaccine candidate, vla2001, with the medicines and healthcare products regulatory agency (mhra) in the united kingdom (uk). vla2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials in europe.
VALN Ratings Summary
VALN Quant Ranking